NANJING, China, Feb. 11, 2011 /PRNewswire-Asia/ — Simcere
Pharmaceutical Group (“Simcere” or the “Company”) (NYSE:
SCR), a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced the
appointment of Mr. Hong Zhao, a highly regarded executive in the
Chinese pharmaceutical industry, as its executive vice president of
sales and marketing, effective February 12, 2011.
“Mr. Zhao is highly respected in the Chinese pharmaceutical
industry,” said Mr. Jinsheng Ren, Chairman and Chief Executive
Officer of Simcere. “Mr. Zhao has nearly 20 years’ experience in
the pharmaceutical industry with a proven track record of
leadership and performance. We warmly welcome Mr. Zhao who
will help strengthen our leadership team and better position our
business for sustainable growth.”
Mr. Zhao commented, “I am delighted to be joining Simcere, an
energetic and promising company that I have long admired for its
value and vision. I am looking forward to working with such an
innovative team to enhance the competitiveness of Simcere and help
make a difference to the healthcare industry in China.”
Mr. Hong Zhao joined the industry in 1992. He started as a
pharmaceutical sales representative and took on positions of
increasing responsibilities in sales & marketing with Xian
Janssen and Novartis China. He most recently held the position of
Senior Vice President of Novartis Greater China and General Manager
of Novartis Shanghai. Mr. Zhao received an EMBA degree from China
Europe International Business School (CEIBS), and a bachelor’s
degree in Medicine from Nanjing Medical University.
About Simcere Pharmaceutical GroupSimcere Pharmaceutical
Group (NYSE: SCR, Simcere) is a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of
brand
‘/>”/>